Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
-
Alleged Bondi shooters conducted 'tactical' training in countryside, Australian police say
-
Swiss court to hear landmark climate case against cement giant
-
Knicks' Brunson scores 47, Bulls edge Hawks epic
-
Global nuclear arms control under pressure in 2026
-
Asian markets rally with Wall St as rate hopes rise, AI fears ease
-
Jailed Malaysian ex-PM Najib loses bid for house arrest
-
Banned film exposes Hong Kong's censorship trend, director says
-
Duffy, Patel force West Indies collapse as NZ close in on Test series win
-
Australian state pushes tough gun laws, 'terror symbols' ban after shooting
-
A night out on the town during Nigeria's 'Detty December'
-
US in 'pursuit' of third oil tanker in Caribbean: official
-
CO2 soon to be buried under North Sea oil platform
-
Steelers edge Lions as Bears, 49ers reach playoffs
-
India's Bollywood counts costs as star fees squeeze profits
-
McCullum admits errors in Ashes preparations as England look to salvage pride
-
Pets, pedis and peppermints: When the diva is a donkey
-
'A den of bandits': Rwanda closes thousands of evangelical churches
-
Southeast Asia bloc meets to press Thailand, Cambodia on truce
-
As US battles China on AI, some companies choose Chinese
-
AI resurrections of dead celebrities amuse and rankle
-
Steelers receiver Metcalf strikes Lions fan
-
Morocco coach 'taking no risks' with Hakimi fitness
-
Gang members given hundreds-years-long sentences in El Salvador
-
Chargers, Bills edge closer to playoff berths
-
Gang members given hundred-years-long sentences in El Salvador
-
Hosts Morocco off to winning start at Africa Cup of Nations
-
No jacket required for Emery as Villa dream of title glory
-
Amorim fears United captain Fernandes will be out 'a while'
-
Nigerian government frees 130 kidnapped Catholic schoolchildren
-
Captain Kane helps undermanned Bayern go nine clear in Bundesliga
-
Captain Kane helps undermanned Bayern go nine clear
-
Rogers stars as Villa beat Man Utd to boost title bid
-
Barca strengthen Liga lead at Villarreal, Atletico go third
-
Third 'Avatar' film soars to top in N. American box office debut
-
Third day of Ukraine settlement talks to begin in Miami
-
Barcelona's Raphinha, Yamal strike in Villarreal win
-
Macron, on UAE visit, announces new French aircraft carrier
-
Barca's Raphinha, Yamal strike in Villarreal win
-
Gunmen kill 9, wound 10 in South Africa bar attack
-
Allegations of new cover-up over Epstein files
-
Atletico go third with comfortable win at Girona
-
Schwarz breaks World Cup duck with Alta Badia giant slalom victory
-
Salah unaffected by Liverpool turmoil ahead of AFCON opener - Egypt coach
-
Goggia eases her pain with World Cup super-G win as Vonn takes third
-
Goggia wins World Cup super-G as Vonn takes third
-
Cambodia says Thai border clashes displace over half a million
-
Kremlin denies three-way US-Ukraine-Russia talks in preparation
-
Williamson says 'series by series' call on New Zealand Test future
-
Taiwan police rule out 'terrorism' in metro stabbing
-
Australia falls silent, lights candles for Bondi Beach shooting victims
NYSE - LSE
Altamira Therapeutics to Host First Half 2025 Financial Results and Business Update Call on August 29, 2025
HAMILTON, BERMUDA / ACCESS Newswire / August 26, 2025 / Altamira Therapeutics Ltd. ("Altamira" or the "Company") (OTCQB:CYTOF), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that it will host its Half Year 2025 Financial Results and Business Update Call on Friday, August 29, 2025. Founder, Chairman, and CEO Thomas Meyer and COO Covadonga Pañeda will deliver prepared remarks.
Event: Altamira Therapeutics First Half 2025 Financial Results and Business Update Call
Date: Friday, August 29, 2025
Time: 8:00 am ET
Access:
Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 427043
Webcast URL: https://www.webcaster4.com/Webcast/Page/2797/52765
Participants will be greeted by an operator and asked for the access code. If a caller does not have the code, they can reference the company name.
The call will be in listen-only mode.
A replay of the call will be available 30 minutes after the live event via the Investors section of the Altamira website at https://ir.altamiratherapeutics.com/.
Replay access:
Toll Free: 877-481-4010
International: 919-882-2331
Replay Passcode: 52765
Expiration: Friday, September 12, 2025
About Altamira Therapeutics
Altamira Therapeutics (OTCQB:CYTOF) is developing and supplying peptide-based nanoparticle technologies for efficient RNA delivery to extrahepatic tissues (xPhore™ platform). The Company currently has two flagship siRNA programs using its proprietary delivery technology: AM-401 for KRAS driven cancer and AM-411 for rheumatoid arthritis, both in preclinical development beyond in vivo proof of concept. The versatile delivery platform is also suited for mRNA and other RNA modalities and made available to pharma or biotech companies through out-licensing. In addition, Altamira holds a 49% stake (with additional economic rights) in Altamira Medica AG, which holds its commercial-stage legacy asset Bentrio®, an OTC nasal spray for allergic rhinitis. Further, the Company is in the process of partnering / divesting its inner ear legacy assets. Founded in 2003, Altamira is headquartered in Hamilton, Bermuda, with its main operations in Basel, Switzerland. For more information, visit: https://altamiratherapeutics.com/
Investor Contact
SOURCE: Altamira Therapeutics
View the original press release on ACCESS Newswire
Y.Aukaiv--AMWN